tiprankstipranks
GoodRx Holdings (GDRX)
NASDAQ:GDRX
US Market
Want to see GDRX full AI Analyst Report?

GoodRx Holdings (GDRX) Stock Forecast & Price Target

1,323 Followers
See the Price Targets and Ratings of:

GDRX Analyst Ratings

Hold
13Ratings
Hold
4 Buy
7 Hold
2 Sell
Based on 13 analysts giving stock ratings to
GoodRx
Holdings
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GDRX Stock 12 Month Forecast

Average Price Target

$3.04
▲(33.92% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for GoodRx Holdings in the last 3 months. The average price target is $3.04 with a high forecast of $4.00 and a low forecast of $1.90. The average price target represents a 33.92% change from the last price of $2.27.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","1.5":"$1.5","4.5":"$4.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.04,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.04</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.90</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.5,3,4.5,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.55,2.6615384615384614,2.773076923076923,2.8846153846153846,2.996153846153846,3.1076923076923078,3.2192307692307693,3.3307692307692305,3.4423076923076925,3.5538461538461537,3.6653846153846157,3.776923076923077,3.8884615384615384,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.55,2.5876923076923077,2.625384615384615,2.663076923076923,2.7007692307692306,2.7384615384615385,2.776153846153846,2.813846153846154,2.8515384615384614,2.8892307692307693,2.9269230769230767,2.9646153846153847,3.002307692307692,{"y":3.04,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.55,2.5,2.4499999999999997,2.4,2.3499999999999996,2.3,2.25,2.1999999999999997,2.15,2.0999999999999996,2.05,2,1.9499999999999997,{"y":1.9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.82,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.74,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.17,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$4.00Average Price Target$3.04Lowest Price Target$1.90
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen
$3$4
Buy
76.21%
Upside
Assigned
05/11/26
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (NASDAQ: GDRX) and DaVita (NYSE: DVA)
Goldman Sachs Analyst forecast on GDRX
Goldman Sachs
Goldman Sachs
$2.5$3.5
Hold
54.19%
Upside
Reiterated
05/08/26
Goldman Sachs Keeps Their Hold Rating on GoodRx Holdings (GDRX)
Wells Fargo Analyst forecast on GDRX
Wells Fargo
Wells Fargo
$3.5
Buy
54.19%
Upside
Reiterated
05/08/26
Analyst Maintains Buy on GoodRx as High-Value Segments Gain Traction; Price Target Kept at $3.50
Truist Financial Analyst forecast on GDRX
Truist Financial
Truist Financial
Hold
Reiterated
05/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pennant Group (NASDAQ: PNTG), GoodRx Holdings (NASDAQ: GDRX) and Cross Country Healthcare (NASDAQ: CCRN)
Raymond James Analyst forecast on GDRX
Parker Snure
Raymond James
Not Ranked
Raymond James
Buy
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (NASDAQ: GDRX), Compass Therapeutics (NASDAQ: CMPX) and Addus Homecare (NASDAQ: ADUS)
Barclays
$3
Sell
32.16%
Upside
Reiterated
03/30/26
Barclays Keeps Their Sell Rating on GoodRx Holdings (GDRX)
Citi
$4.5$3.5
Buy
54.19%
Upside
Reiterated
03/03/26
GoodRx price target lowered to $3.50 from $4.50 at CitiGoodRx price target lowered to $3.50 from $4.50 at Citi
Deutsche Bank  Analyst forecast on GDRX
Deutsche Bank
Deutsche Bank
$6$3
Hold
32.16%
Upside
Reiterated
02/27/26
GoodRx price target lowered to $3 from $6 at Deutsche BankGoodRx price target lowered to $3 from $6 at Deutsche Bank
Morgan Stanley Analyst forecast on GDRX
Morgan Stanley
Morgan Stanley
$4$3
Hold
32.16%
Upside
Reiterated
02/27/26
Analysts Conflicted on These Healthcare Names: Syndax Pharmaceuticals (NASDAQ: SNDX), Alector (NASDAQ: ALEC) and GoodRx Holdings (NASDAQ: GDRX)
UBS
$4$2
Hold
-11.89%
Downside
Reiterated
02/27/26
UBS Sticks to Their Hold Rating for GoodRx Holdings (GDRX)
Mizuho Securities Analyst forecast on GDRX
Mizuho Securities
Mizuho Securities
$4$3
Hold
32.16%
Upside
Reiterated
02/27/26
GoodRx price target lowered to $3 from $4 at MizuhoGoodRx price target lowered to $3 from $4 at Mizuho
Bank of America Securities Analyst forecast on GDRX
Bank of America Securities
Bank of America Securities
$2.6$1.9
Sell
-16.30%
Downside
Reiterated
02/26/26
GoodRx: Weakened Long‑Term Outlook and Structural Headwinds Support Sell Rating
J.P. Morgan Analyst forecast on GDRX
J.P. Morgan
J.P. Morgan
Hold
Downgraded
02/26/26
GoodRx downgraded to Neutral from Overweight at JPMorganGoodRx downgraded to Neutral from Overweight at JPMorgan
Jefferies
$5.25$2.75
Hold
21.15%
Upside
Downgraded
01/22/26
GoodRx downgraded to Hold from Buy at JefferiesGoodRx downgraded to Hold from Buy at Jefferies
Leerink Partners Analyst forecast on GDRX
Leerink Partners
Leerink Partners
Buy
Reiterated
10/02/25
We reiterate our Outperform rating on GDRX on this potential significant positive update.
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen
$3$4
Buy
76.21%
Upside
Assigned
05/11/26
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (NASDAQ: GDRX) and DaVita (NYSE: DVA)
Goldman Sachs Analyst forecast on GDRX
Goldman Sachs
Goldman Sachs
$2.5$3.5
Hold
54.19%
Upside
Reiterated
05/08/26
Goldman Sachs Keeps Their Hold Rating on GoodRx Holdings (GDRX)
Wells Fargo Analyst forecast on GDRX
Wells Fargo
Wells Fargo
$3.5
Buy
54.19%
Upside
Reiterated
05/08/26
Analyst Maintains Buy on GoodRx as High-Value Segments Gain Traction; Price Target Kept at $3.50
Truist Financial Analyst forecast on GDRX
Truist Financial
Truist Financial
Hold
Reiterated
05/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pennant Group (NASDAQ: PNTG), GoodRx Holdings (NASDAQ: GDRX) and Cross Country Healthcare (NASDAQ: CCRN)
Raymond James Analyst forecast on GDRX
Parker Snure
Raymond James
Not Ranked
Raymond James
Buy
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (NASDAQ: GDRX), Compass Therapeutics (NASDAQ: CMPX) and Addus Homecare (NASDAQ: ADUS)
Barclays
$3
Sell
32.16%
Upside
Reiterated
03/30/26
Barclays Keeps Their Sell Rating on GoodRx Holdings (GDRX)
Citi
$4.5$3.5
Buy
54.19%
Upside
Reiterated
03/03/26
GoodRx price target lowered to $3.50 from $4.50 at CitiGoodRx price target lowered to $3.50 from $4.50 at Citi
Deutsche Bank  Analyst forecast on GDRX
Deutsche Bank
Deutsche Bank
$6$3
Hold
32.16%
Upside
Reiterated
02/27/26
GoodRx price target lowered to $3 from $6 at Deutsche BankGoodRx price target lowered to $3 from $6 at Deutsche Bank
Morgan Stanley Analyst forecast on GDRX
Morgan Stanley
Morgan Stanley
$4$3
Hold
32.16%
Upside
Reiterated
02/27/26
Analysts Conflicted on These Healthcare Names: Syndax Pharmaceuticals (NASDAQ: SNDX), Alector (NASDAQ: ALEC) and GoodRx Holdings (NASDAQ: GDRX)
UBS
$4$2
Hold
-11.89%
Downside
Reiterated
02/27/26
UBS Sticks to Their Hold Rating for GoodRx Holdings (GDRX)
Mizuho Securities Analyst forecast on GDRX
Mizuho Securities
Mizuho Securities
$4$3
Hold
32.16%
Upside
Reiterated
02/27/26
GoodRx price target lowered to $3 from $4 at MizuhoGoodRx price target lowered to $3 from $4 at Mizuho
Bank of America Securities Analyst forecast on GDRX
Bank of America Securities
Bank of America Securities
$2.6$1.9
Sell
-16.30%
Downside
Reiterated
02/26/26
GoodRx: Weakened Long‑Term Outlook and Structural Headwinds Support Sell Rating
J.P. Morgan Analyst forecast on GDRX
J.P. Morgan
J.P. Morgan
Hold
Downgraded
02/26/26
GoodRx downgraded to Neutral from Overweight at JPMorganGoodRx downgraded to Neutral from Overweight at JPMorgan
Jefferies
$5.25$2.75
Hold
21.15%
Upside
Downgraded
01/22/26
GoodRx downgraded to Hold from Buy at JefferiesGoodRx downgraded to Hold from Buy at Jefferies
Leerink Partners Analyst forecast on GDRX
Leerink Partners
Leerink Partners
Buy
Reiterated
10/02/25
We reiterate our Outperform rating on GDRX on this potential significant positive update.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering GoodRx Holdings

3 Months
xxx
Success Rate
15/21 ratings generated profit
71%
Average Return
+8.50%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +8.50% per trade.
1 Year
Allen LutzBank of America Securities
Success Rate
19/21 ratings generated profit
90%
Average Return
+27.92%
Copying Allen Lutz's trades and holding each position for 1 Year would result in 90.48% of your transactions generating a profit, with an average return of +27.92% per trade.
2 Years
xxx
Success Rate
19/21 ratings generated profit
90%
Average Return
+31.99%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 90.48% of your transactions generating a profit, with an average return of +31.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GDRX Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
4
4
8
7
4
Buy
0
0
0
0
3
Hold
7
9
10
8
4
Sell
5
4
4
2
1
Strong Sell
0
0
0
0
0
total
16
17
22
17
12
In the current month, GDRX has received 7 Buy Ratings, 4 Hold Ratings, and 1 Sell Ratings. GDRX average Analyst price target in the past 3 months is 3.04.
Each month's total comprises the sum of three months' worth of ratings.

GDRX Financial Forecast

GDRX Earnings Forecast

Next quarter’s earnings estimate for GDRX is $0.08 with a range of $0.07 to $0.11. The previous quarter’s EPS was $0.07. GDRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GDRX has Performed in-line its overall industry.
Next quarter’s earnings estimate for GDRX is $0.08 with a range of $0.07 to $0.11. The previous quarter’s EPS was $0.07. GDRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GDRX has Performed in-line its overall industry.

GDRX Sales Forecast

Next quarter’s sales forecast for GDRX is $191.94M with a range of $188.40M to $196.20M. The previous quarter’s sales results were $194.01M. GDRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GDRX has Performed in-line its overall industry.
Next quarter’s sales forecast for GDRX is $191.94M with a range of $188.40M to $196.20M. The previous quarter’s sales results were $194.01M. GDRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GDRX has Performed in-line its overall industry.

GDRX Stock Forecast FAQ

What is GDRX’s average 12-month price target, according to analysts?
Based on analyst ratings, GoodRx Holdings’s 12-month average price target is 3.04.
    What is GDRX’s upside potential, based on the analysts’ average price target?
    GoodRx Holdings has 33.92% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GDRX a Buy, Sell or Hold?
          GoodRx Holdings has a consensus rating of Hold which is based on 4 buy ratings, 7 hold ratings and 2 sell ratings.
            What is GoodRx Holdings’s price target?
            The average price target for GoodRx Holdings is 3.04. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $4.00 ,the lowest forecast is $1.90. The average price target represents 33.92% Increase from the current price of $2.27.
              What do analysts say about GoodRx Holdings?
              GoodRx Holdings’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of GDRX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.